PA Medical News about Rituximab

Your Unread Messages

See All

Hello, Mary O'connor
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Use of Antiemetic Agents in Acute Gastroenteritis

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Prevention of hepatitis B virus reactivation under rituximab therapy
Immunotherapy, 11/06/09

Tsutsumi Y et al. – Rituximab is a useful drug for the treatment of B–cell non–Hodgkin’s lymphoma, and its use has been extended to other diseases such as idiopathic thrombocytopenic purpura and chronic rheumatoid arthritis. One serious complication associated with rituximab use is reactivation of hepatitis B virus, and the search for methods to prevent this occurrence has resulted in a rapid accumulation of knowledge in recent years.

<< Previous
Topical Pimecrolimus: A Review of its Use in the Management of...

Next >>
The role of mitochondrial proteins in sperm capacitation

Treatment of adult inflammatory myositis with rituximab: An emerging therapy for refractory patients
Journal of Clinical Rheumatology (JCR), 10/08/09 Relevance Score: 90%

Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection
Nephrology, 10/07/09 Relevance Score: 89%

Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: Effects of rituximab
Annals of Oncology, 11/10/09 Relevance Score: 88%

Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögrens syndrome
Arthritis & Rheumatism, 11/06/09 Relevance Score: 87%

Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy
Annals of Oncology, 11/06/09 Relevance Score: 87%